🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI

Recruitingn/aAges 18 Years - anyAllAssiut University
NCT07202845 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable muscle-invasive bladder cancer (MIBC). However, non-response to NAC can lead to delayed surgery and unnecessary toxicity. Magnetic resonance imaging (MRI), particularly multiparametric MRI (mpMRI) with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), offers functional and quantitative biomarkers that may predict NAC response early in treatment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients diagnosed with cT2-T4 urothelial carcinoma of the urinary bladder, according to the TNM classification (8), who give informed, written consent on participation in the study and approve all its requirements. * Planned to receive cisplatin-based NAC followed by radical cystectomy. * Willing to undergo three mpMRI scans (baseline, 24h post-initial cisplatin, and post-NAC). Exclusion Criteria: * Patients who have received pelvic radiotherapy. * Severe renal impairment * Previous open or laparoscopic pelvic surgery. * Presence of distant metastases at diagnosis. * Patients with contraindications to MRI. * Ineligibility to cisplatin
💊

What it tests

  • Multiparametric Magnetic Resonance Imaging (mpMRI)
📍

Where

1 site
Amr E. Darwish
Asyut, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy